Considering the information discussed, it is highly possible that FGF21 could be a universal cancer biomarker rather than a specific diagnosis biomarker for ccRCC, and it should be used in combination with other existing biomarkers. The gene discussed is FGF21; the disease is nonpapillary renal cell carcinoma.